DRUG-INDUCED LIVER INJURY - MODERN VIEW ON THE CORRECT PROBLEM
Introduction. The high prevalence, variability of clinical manifestations, limited knowledge about the mechanisms of toxicity, the complexity of diagnosis makes drug-induced liver injury one of the unsolved problems in clinical medicine. The expansion of the pharmaceutical market, the growth in the number of uncontrolled medications put forward drug-induced liver damage in a number of urgent problems not only for hepatologists, but also for doctors of other specialties. Aim. Review of current scientific publications devoted to the study of drug-induced liver damage. Material and methods. A search and subsequent analysis of scientific publications devoted to the study of the issue of diagnosis and treatment of drug-induced liver lesions, published on the databases: Unpaywall, PubMed, eLibrary, CyberLeninka, MedLine, was carried out. Results and discussion. The article presents up-to-date data on the pathogenesis of occurrence, classification features, principles of diagnosis and treatment of drug-induced liver lesions. Pharmaceuticals that most commonly cause drug-induced liver injury are listed. Conclusion. Drug-induced liver injury covers a wide range of clinical conditions, ranging from mild abnormalities in biochemical parameters to acute liver failure. The vast majority of adverse liver reactions occur from 5-90 days after the last dose of inducer drugs. Many scientific papers have been devoted to the study of drug-induced liver injury, but clinical practitioners still have many unresolved issues related to the correct diagnosis and treatment of drug-induced liver injury. This is facilitated primarily by the uncontrolled prescription and intake of pharmaceuticals, the «fashion» for biologically active additives, which in its outcome forms the development of polypharmacy and, accordingly, the potentiation of hepatotoxicity of drugs.